BMY - 3 Things In Biotech August 9: Clovis Looks Forward In Ovarian Cancer
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Clovis's portents of irrelevance not recognized by the company, presses on with combo study in ovarian
Company: Bristol-Myers Squibb (BMY) and Clovis Oncology (CLVS)
Therapy: Nivolumab and rucaparib
Disease: Ovarian cancer
News: CLVS announced that it has randomized the first patient into the phase 3 ATHENA study, which is assessing the combination of their PARP inhibitor with BMY's nivolumab for